137 related articles for article (PubMed ID: 38166810)
1. Prognostic factors of patients with recurrent uterine malignancies undergoing secondary cytoreductive surgery.
Fang C; Zhang Y; Zhang P; Zhu T
BMC Womens Health; 2024 Jan; 24(1):9. PubMed ID: 38166810
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
Zou RY; Yuan L; Chen M; Yao LQ
Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
[No Abstract] [Full Text] [Related]
3. Predictors of favorable survival after secondary cytoreductive surgery for recurrent endometrial cancer.
Shikama A; Minaguchi T; Takao W; Hosokawa Y; Nishida K; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
Int J Clin Oncol; 2019 Oct; 24(10):1256-1263. PubMed ID: 31098693
[TBL] [Abstract][Full Text] [Related]
4. Non-exenterative surgical management of recurrent endometrial carcinoma.
Moukarzel LA; Braxton KF; Zhou QC; Pedra Nobre S; Iasonos A; Alektiar KM; Tew WP; Abu-Rustum NR; Leitao MM; Chi DS; Mueller JJ
Gynecol Oncol; 2021 Aug; 162(2):268-276. PubMed ID: 34090704
[TBL] [Abstract][Full Text] [Related]
5. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
[TBL] [Abstract][Full Text] [Related]
6. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
7. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
Fan XM; Zhang J; Niu SH; Li KX; Song CZ
Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
[TBL] [Abstract][Full Text] [Related]
8. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.
Jeong SY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS; Lee YY
J Ovarian Res; 2019 Dec; 13(1):1. PubMed ID: 31892329
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery in recurrent endometrial cancer: A new paradigm for surgical management?
Dhanis J; Blake D; Rundle S; Pijnenborg JMA; Smits A
Surg Oncol; 2022 Aug; 43():101811. PubMed ID: 35849994
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients.
So M; Miyamoto T; Murakami R; Abiko K; Hamanishi J; Baba T; Mandai M
J Gynecol Oncol; 2019 Nov; 30(6):e100. PubMed ID: 31576692
[TBL] [Abstract][Full Text] [Related]
11. Salvage Cytoreductive Surgery for Recurrent Endometrial Cancer.
Turan T; Tasci T; Karalok A; Ureyen I; Kocak O; Turkmen O; Basaran D; Tulunay G
Int J Gynecol Cancer; 2015 Nov; 25(9):1623-32. PubMed ID: 26397154
[TBL] [Abstract][Full Text] [Related]
12. Optimum selection criteria for secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer: A multicenter study from the Gynecologic Oncology Research Investigators coLLaborAtion group (GORILLA-3001).
Son JH; Kong TW; Park SJ; Lee EJ; Kim HS; Kim NK; Kim Y; Hwang WY; Suh DH; Kim TH; Yang EJ; Shim SH; Chang SJ
J Surg Oncol; 2023 Sep; 128(4):645-652. PubMed ID: 37126413
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Petrillo M; De Iaco P; Cianci S; Perrone M; Costantini B; Ronsini C; Scambia G; Fagotti A
Ann Surg Oncol; 2016 May; 23(5):1660-5. PubMed ID: 26714958
[TBL] [Abstract][Full Text] [Related]
14. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
15. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Goldberg RM; Kim SR; Fazelzad R; Li X; Brown TJ; May T
Gynecol Oncol; 2022 Jan; 164(1):212-220. PubMed ID: 34756470
[TBL] [Abstract][Full Text] [Related]
17. Surgical cytoreduction for recurrent epithelial ovarian cancer.
Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
[TBL] [Abstract][Full Text] [Related]
18. Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
Janco JM; Kumar A; Weaver AL; McGree ME; Cliby WA
Gynecol Oncol; 2016 Apr; 141(1):140-7. PubMed ID: 26836496
[TBL] [Abstract][Full Text] [Related]
19. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index.
Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J;
World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831
[TBL] [Abstract][Full Text] [Related]
20. Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer.
Bogani G; Rossetti D; Ditto A; Martinelli F; Chiappa V; Mosca L; Leone Roberti Maggiore U; Ferla S; Lorusso D; Raspagliesi F
J Gynecol Oncol; 2018 Sep; 29(5):e66. PubMed ID: 30022630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
